| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +6,546 | +16% | $0.000000 | 47,209 | 16 Feb 2023 | Direct | F1 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +5,074 | +11% | $0.000000 | 52,283 | 16 Feb 2023 | Direct | F2 |
| transaction | ABBV | Common Stock, $0.01 par value | Options Exercise | $444,566 | +7,809 | +15% | $56.93 | 60,092 | 21 Feb 2023 | Direct | |
| transaction | ABBV | Common Stock, $0.01 par value | Options Exercise | $428,382 | +6,370 | +11% | $67.25 | 66,462 | 21 Feb 2023 | Direct | |
| transaction | ABBV | Common Stock, $0.01 par value | Sale | $846,237 | -5,615 | -8.4% | $150.71 | 60,847 | 21 Feb 2023 | Direct | F3 |
| transaction | ABBV | Common Stock, $0.01 par value | Sale | $1,176,958 | -7,780 | -13% | $151.28 | 53,067 | 21 Feb 2023 | Direct | F4 |
| transaction | ABBV | Common Stock, $0.01 par value | Sale | $984,784 | -6,533 | -12% | $150.74 | 46,534 | 21 Feb 2023 | Direct | F5 |
| transaction | ABBV | Common Stock, $0.01 par value | Sale | $1,156,763 | -7,646 | -16% | $151.29 | 38,888 | 21 Feb 2023 | Direct | F6 |
| transaction | ABBV | Common Stock, $0.01 par value | Sale | $85,492 | -567 | -1.5% | $150.78 | 38,321 | 21 Feb 2023 | Direct | F7 |
| transaction | ABBV | Common Stock, $0.01 par value | Sale | $60,536 | -400 | -1% | $151.34 | 37,921 | 21 Feb 2023 | Direct | F8 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to Buy) | Award | $0 | +16,205 | $0.000000 | 16,205 | 16 Feb 2023 | Common Stock | 16,205 | $149.62 | Direct | F9 | |
| transaction | ABBV | Option (Right to Buy) | Options Exercise | $444,566 | -7,809 | -100% | $56.93 | 0 | 21 Feb 2023 | Common Stock | 7,809 | $56.93 | Direct | F10 |
| transaction | ABBV | Option (Right to Buy) | Options Exercise | $428,382 | -6,370 | -100% | $67.25 | 0 | 21 Feb 2023 | Common Stock | 6,370 | $67.25 | Direct | F10 |
| Id | Content |
|---|---|
| F1 | Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| F2 | Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. |
| F3 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.51, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.10, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.15 to $151.42, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F9 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,402 on February 16, 2024, 5,402 on February 16, 2025, and 5,401 on February 16, 2026. |
| F10 | Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).